Nerve-Sparing radiation may help men keep sexual function after prostate cancer treatment
NCT ID NCT03525262
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether a special type of radiation therapy (SAbR) that avoids the nerves involved in erections can help preserve sexual function in men with localized prostate cancer. About 124 men will be randomly assigned to receive standard SAbR or a version that spares these nerves. The main goal is to see if the nerve-sparing approach leads to less decline in erectile function, while still controlling the cancer effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic ablative body radiotherapy (SAbR) with or without neurovascular sparing
What this could lead to
If successful, this approach could help men with prostate cancer maintain sexual function after radiotherapy without compromising cancer treatment.
What could go wrong
This is a phase 2 trial with only 124 participants, so results may not apply to everyone. The nerve-sparing technique might not preserve function as hoped, or could increase the risk of cancer recurrence in the spared area.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Penn Medicine Radiation Oncology
Philadelphia, Pennsylvania, 19104, United States
-
Penrose Hospital
Colorado Springs, Colorado, 80907, United States
-
Stony Brook University Cancer Center
Stony Brook, New York, 11794, United States
-
UCSF ( Department of Radiation Oncology University of California San Francisco)
San Francisco, California, 94143, United States
-
UT Southwestern Cancer Center
Dallas, Texas, 75235, United States
-
University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
University of Michigan- Michigan Medicine
Ann Arbor, Michigan, 48109, United States